


SUPPLEMENTARY DATA


**Supplementary Figure 1.** Surface VTCN1 levels are decreased in residential PLN macrophages from NOD mice in comparison to those from B6<sup>g7</sup> mice. Analysis of VTCN1 intensity on F4/80<sup>+</sup> cells in cells isolated from pancreatic lymph nodes (PLN) by FACS (top). The mean VTCN1 intensity in each F4/80<sup>+</sup> fraction is shown on the lower table.




	<b>Mean VTCN1 intensity</b>
Ig control	474
NOD	635
B6 <sup>g7</sup>	1050

SUPPLEMENTARY DATA

**Supplementary Figure 2.** VTCN1 partially co-localizes with NRD1. Immunofluorescent image of permeabilized mouse P.MΦ stained for VTCN1 (*red*) and NRD1 (*green*). Arrow indicates VTCN1/NRD1 co-localization.



**Supplementary Figure 3.** sVTCN1 levels in peripheral blood do not correlate with age in healthy subjects. Linear regression analysis of ln-transformed sVTCN1 levels and the age of the patients in sVTCN1<sup>+</sup> controls and T1D-relative populations. The p value was calculated by t-statistics for parameter estimate.



SUPPLEMENTARY DATA

**Supplementary Table 1.** List of the primers used in current study.

gene	direction	primer sequence/source	amplicon size (bp)
mouse <i>β-actin</i>	F/R	QIAGEN; cat#PPM02945B	154
mouse <i>GAPDH</i>	F/R	QIAGEN; cat#PPM02946E	140
human <i>β-actin</i>	F/R	QIAGEN; cat#PPH00073G	174
human <i>GAPDH</i>	F/R	QIAGEN; cat# PPH00150F	130
mouse <i>VTCN1</i>	F	5'-CTTTGGCATTTCAGGCAAGCA-3'	103
	R	5'-TGATGTCAGGTTCAAAGTGCAG-3'	
human <i>VTCN1</i>	F	5'-GGGCAGATCCTCTTCTGGAG-3'	121
	R	5'-GCTGAGGCGACAGTAGTGAC-3'	
mouse <i>NRD1</i>	F	5'-TGCTCGTCTAGGAGCGGAT-3'	130
	R	5'-CCTGCAAGCCATTCTGTAATTTG-3'	
mouse <i>PCSK2</i>	F	5'-GTGTGATGGTTTTTGCCTCTG-3'	129
	R	5'-GGGAGCTTTCGGACTCCAA-3'	
mouse <i>PCSK1</i>	F	5'-TCTGCCATCGCCGAAGAAC-3'	157
	R	5'-CCCACGTCACACGATCATCAT-3'	
<i>F4/80</i>	F	5'-CCCCAGTGTCTTACAGAGTG-3'	102
	R	5'-GTGCCAGAGTGGATGTCT-3'	
<i>PCSK1N</i>	F	5'-ACGAGACTCCTGACGTGGA-3'	125
	R	5'-ATCCGCCCTAGCAAGTACCT-3'	

SUPPLEMENTARY DATA

**Supplementary Table 2.** List of the antibodies used in current study.

<b>Method</b>	<b>Primary or capturing antibody (conc. and commercial source); conjugate</b>	<b>Secondary or detection antibody (conc. and commercial source); conjugate</b>
IF	Rat anti-mouse B7-H4 (5µg/ml; R&D Systems)	Donkey anti-rat (1µg/ml; Jackson Immunoresearch); AlexaFluor-594
	Mouse anti-human B7-H4 (5µg/ml; eBioscience)	Donkey anti-mouse (1µg/ml; Jackson Immunoresearch); AlexaFluor-594
	Rabbit anti-mouse NRD1 (2.5µg/ml; Proteintech)	Donkey anti-mouse (1µg/ml; Jackson Immunoresearch); AlexaFluor-488
	Rat anti-mouse F4/80 (10µg/ml; BioLegend); AlexaFluor-488	N/A
	Mouse anti-human CD14 (20 µl/test; BioLegend); FITC	N/A
FACS	Rat anti-mouse B7-H4 (4µg/ml; eBioscience); PE	N/A
	Rat anti-mouse F4/80 (10µg/ml; BioLegend); AlexaFluor-488	N/A
	Mouse anti-human B7-H4 (5µg/ml; eBioscience)	Donkey anti-mouse (5µg/ml; Jackson Immunoresearch); PE
	Mouse anti-human CD14 (BioLegend); FITC	N/A
WB	Goat anti-B7-H4 (1µg/ml; LifeSpan Biosciences)	Donkey anti-goat (0.2µg/ml; Jackson Immunoresearch); HRP
	Rabbit anti-mouse NRD1 (1µg/ml; Abcam, respectively)	Donkey anti-rabbit (0.1µg/ml; Jackson Immunoresearch); HRP
	Rabbit anti-GAPDH (Proteintech)	Donkey anti-rabbit (0.1µg/ml; Jackson Immunoresearch); HRP
ELISA	Mouse anti-human B7-H4 (1µg/ml; eBioscience); <b>capturing</b> antibody	N/A
	Rat anti-mouse B7-H4 (1µg/ml; R&D Systems); <b>capturing</b> antibody	N/A
	Goat anti-B7-H4 (0.5µg/ml; LifeSpan Biosciences); <b>detection</b> antibody	Donkey anti-goat (0.2µg/ml; Jackson Immunoresearch); HRP